Catabasis is a private, venture-backed biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company’s scientific approach harnesses the beneficial effects of the essential omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which have clinical benefits as treatments for a wide range of diseases, including dyslipidemia, atherosclerosis and inflammatory diseases.
Effectively treating complex human disease requires targeting key biological pathways that are dysregulated. Preclinical studies have demonstrated that the company’s compounds, which are new chemical entities, specifically modulate key nodes that converge upon a biological axis or disease state pathway, providing amplified efficacy and improved safety.
|12/01/11||Series A||8M||SV Life Sciences, Clarus Ventures, MedImmune Ventures, Advanced Technology Ventures||Unknown|